FDA Calendar

PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.

The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.

Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our premium biotech research product and our biotech home page.
Company Name
Novartis AG
1H 2021
FDA decision on ENTRESTO for the proposed indication of heart failure with preserved ejection fraction
CorMedix Inc.
Defencath (NDA)
FDA panel to review Defencath to be used as a catheter lock solution in hemodialysis patients
On Nov.18, 2020, the FDA cancelled the Advisory Committee to review Defencath-
Merck & Co Inc.
FDA decision on Vericiguat in Patients with symptomatic chronic Heart Failure and Reduced Ejection Fraction
FDA approved Vericiguat under brand name Verquvo for heart failure with reduced ejection fraction on Jan.19, 2021-
Aurinia Pharmaceuticals Inc.
Voclosporin (NDA)
FDA decision on Voclosporin for the treatment of lupus nephritis
FDA approved LUPKYNIS (voclosporin) for adult patients with active Lupus Nephritis on Jan.22, 2021-
Amgen Inc.
Nplate (sBLA)
FDA decision on Nplate for the treatment of Hematopoietic Syndrome of Acute Radiation Syndrome
Adamas Pharmaceuticals Inc
FDA decision on GOCOVRI as treatment for OFF episodes in Parkinson’s disease patients receiving levodopa-based therapy
Mallinckrodt plc
StrataGraft (BLA)
FDA decision on StrataGraft for the treatment of adult patients with deep partial-thickness thermal burns.
Regeneron Pharmaceuticals
Evinacumab (BLA)
FDA decision on Evinacumab as an adjunct to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia
TG Therapeutics Inc.
Umbralisib (NDA)
FDA decision on Umbralisib as a treatment for patients with previously treated marginal zone lymphoma
G1 Therapeutics, Inc.
Trilaciclib (NDA)
FDA decision on trilaciclib for small cell lung cancer patients being treated with chemotherapy

ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.

Buy this Content

merck jan26 Today's Daily Dose brings you news about Merck discontinuing its work on COVID-19 vaccines, Moderna advancing its vaccine research to defeat the emerging strains of SARS-CoV-2 virus and AstraZeneca rubbishing German media reports related to AZD1222 vaccine.
stockmarkets jan07 22jan21 What's moving these stocks in pre-market hours today?
biotech jan22 Today's Daily Dose brings you news about the effectiveness of Lilly's Bamlanivimab in reducing the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, executive changes at BiondVax Pharma, regulatory update on Genetic Technologies' COVID-19 PRS Test, Adamis' SYMJEPI products being made available in the Walgreens Prescription Savings Club, to name a few.
Read More
In an action to reduce the spread of COVID-19 through travel, President Joe Biden signed a presidential proclamation imposing air travel restrictions on incoming non-US travelers to the United States from 26 European countries in the Schengen Zone, the UK, Ireland and Brazil. In the light of the more contagious new variant of the coronavirus, South Africa also has been added to the restricted lis
In what is touted as a hopeful sign, COVID-19 cases and hospitalizations in the United States continues to trend downward. COVID-19 hospitalizations in the country fell to the lowest figure in 42 days. 109,936 people are currently admitted in U.S. hospitals with coronavirus infection, which is the fewest since December 14, according to the latest data by COVID Tracking Project. Out of this, 20,87
Valens Co. Inc., a Canada-based manufacturer of cannabis derivatives products, said it has agreed to acquire all of the issued and outstanding shares of LYF Food Technologies Inc. for C$24.9 million in a cash and share transaction. The deal also includes up to an additional C$17.5 million in consideration...
Read More